EC

EcoR1 Capital Portfolio holdings

AUM $2.06B Turnover 46.34%
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$326M
AUM Growth
+$72.3M
Cap. Flow
-$3.11M
Cap. Flow %
-0.95%
Top 10 Hldgs %
66.65%
Holding
46
New
15
Increased
5
Reduced
6
Closed
15
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.4 years
Top 10 Avg Time Held Equity only
0.5 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$13.7M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$13.7M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$8.71M
4
DERM icon
Dermira, Inc.
DERM
+$8.05M
5
KA icon
Kineta, Inc. Common Stock
KA
+$8M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$21.8M
2
CYTK icon
Cytokinetics
CYTK
+$13.5M
3
XLRN
Acceleron Pharma
XLRN
+$12.6M
4
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$9.51M
5
EPZM
Epizyme, Inc
EPZM
+$7.73M

Sector Composition

Rank Sector Weight
1 Healthcare 79.95%
2 Miscellaneous 20.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CMRX icon
26
DELISTED
Chimerix, Inc.
CMRX
$3.31M 1.02%
+598,062
New +$2.74M
2016 Q3
0 quarters
OMED
27
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$3.04M 0.93%
+265,784
New +$3.09M
2016 Q3
0 quarters
FATE icon
28
Fate Therapeutics
FATE
$232M
$1.84M 0.57%
+590,527
New +$1.43M
2016 Q3
0 quarters
SYRS icon
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$882K 0.27%
+6,360
New +$807K
2016 Q3
0 quarters
CASC
30
CALL
DELISTED
Cascadian Therapeutics, Inc.
CASC
$170K 0.05%
+17,300
New +$123K
2016 Q3
0 quarters
AKTX icon
31
Akari Therapeutics
AKTX
$16.6M
– –
-79
Closed -$856K –
COLL icon
32
Collegium Pharmaceutical
COLL
$733M
– –
-281,776
Closed -$3.34M –
EDIT icon
33
Editas Medicine
EDIT
$349M
– –
-85,469
Closed -$2.08M –
ENTA icon
34
Enanta Pharmaceuticals
ENTA
$326M
– –
-136,882
Closed -$3.02M –
TVTX icon
35
Travere Therapeutics
TVTX
$5.02B
– –
-1,225,084
Closed -$21.8M –
XNCR icon
36
Xencor
XNCR
$1.74B
– –
-168,000
Closed -$3.19M –
ITCI icon
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-244,950
Closed -$9.51M –
EIGR
38
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-473
Closed -$281K –
IMGN icon
39
CALL
DELISTED
Immunogen Inc
IMGN
– –
-299,500
Closed -$922K –
EPZM
40
DELISTED
Epizyme, Inc
EPZM
– –
-755,046
Closed -$7.73M –
ADXS
41
DELISTED
Advaxis Inc
ADXS
– –
-6,187
Closed -$751K –
XLRN
42
DELISTED
Acceleron Pharma
XLRN
– –
-371,381
Closed -$12.6M –
FWP
43
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-12,047
Closed -$1.53M –
ARRY icon
44
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-520,000
Closed -$1.85M –
TSRO
45
DELISTED
TESARO, Inc.
TSRO
– –
-9,200
Closed -$773K –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2016 Portfolio in Review

As of Q3 2016, EcoR1 Capital held 46 positions worth $326M, up 28% from $254M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

EcoR1 Capital's Q3 2016 filing shows 15 new, 5 increased, 6 reduced and 15 closed positions. Its largest new stake was Ardelyx: 1,310,023 shares worth $17M. The largest sale was Travere Therapeutics, an estimated $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2016 buy was Ardelyx: 1,310,023 shares worth $17M.
  • EcoR1 Capital added most to Dermira, Inc. in Q3 2016, an estimated $8.05M increase.
  • EcoR1 Capital's biggest Q3 2016 reduction was Cytokinetics, cutting an estimated $13.5M.
  • EcoR1 Capital fully exited Travere Therapeutics in Q3 2016, selling an estimated $21.8M.
  • EcoR1 Capital's ten largest holdings make up 67% of its $326M portfolio in Q3 2016.
  • EcoR1 Capital opened 15 new positions and closed 15 in Q3 2016.
  • EcoR1 Capital's portfolio value rose 28% quarter-over-quarter to $326M.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.